Business
Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™
About this update from Pulse Biosciences, Inc
[{"type":"text","content":" HAYWARD, Calif.--(BUSINESS WIRE)--\nPulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2025.\n\n\nRecent Business Highlights\n\n\nSoft Tissue Ablation\n\n\n\nExpanded the pilot program for the nsPFA Percutaneous Electrode for soft tissue ablation.\n\n\n\nTreated over 140 Benign Thyroid Nodule patients to date across multiple pilot program centers.\n\n\n\nIdentified five sites to participate in a post-market study of the treatment of benign thyroid disease, with plans to commence enrollment in Q3 upon receipt of IRB approvals.\n\n\n\nSurgical AF Ablation\n\n\n\nSubmitted FDA IDE application, including the pivotal study protocol, to support a premarket approval (PMA) application for the treatment of atrial fibrillation (AF) and remain on track to commence the IDE pivotal study in the next few months.\n\n\n\nTreated 40 patients to date and generated positive clinical outcomes, as indicated by follow up remapping procedures, as part of the nsPFA Cardiac Surgery System multi-center, first-in-human AF feasibility study in Europe.\n\n\n\nEndocardial Catheter AF Ablation\n\n\n\nSubmitted FDA IDE application, including the pivotal study protocol, and remain on track to commence the IDE pivotal study in the next few months.\n\n\n\nObserved improved procedure times since last presented at the Heart Rhythm Society 2025 Meeting in April.\n\n\n\nTreated over 140 total patients with the nsPFA 360° catheter to date as part of the multi-center, first-in-human AF study in Europe.\n\n\n\n“We are advancing the top priorities established at the beginning of 2025 for each of our three market development programs,” said Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences. “I am delighted to announce that we have expanded the pilot program for the Percutaneous Electrode for soft tissue ablation, submitted our IDE for both the cardiac surgical clamp and nsPFA 360° catheter, all while continuing to treat more patients and generate positive clinical outcomes with our cardiac devices in their respective feasibility studies in Europe. These achievements further reinforce the transformational potential of nsPFA energy for treating benign thyroid disease...